Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allopurinol for ventricular and supraventricular arrhythmias in patients with implantable cardioverter-defibrillators
IRCT20120520009801N12Phase 3Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ventricular arrhythmia (VA) and Supraventricular arrhythmia (SVA) comparing Allopurinol with Placebo (2 arms). Primary endpoint: Frequency of ventricular and supraventricular arrhythmias. Started Apr 2024; status: completed.
02
Drugs
allopurinol
03
Conditions
ventricular arrhythmia (VA)Supraventricular arrhythmia (SVA)
Beyond the preview
Go deeper on IRCT20120520009801N12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20120520009801N12.